Trial · NCT01431209
Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell Transplant
NCT01431209, Phase 2, Completed, University of Nebraska; results first posted 2021-06-24
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell Transplant. Trials, record NCT01431209. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01431209
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell Transplant
- NCT number
- NCT01431209
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 71 participants, actual
- Lead sponsor
- University of Nebraska
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
- Interventions
- Laboratory Biomarker Analysis, Ruxolitinib Phosphate
- First posted
- 2011-09-09
- Last updated
- 2023-10-05
- Results first posted
- 2021-06-24
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Response Rate | 24 weeks | Number of patients achieving overall response rate |
| Secondary | Overall Survival (OS) | From the date of start of treatment to date of death due to any cause, assessed up to 60 months | The Kaplan-Meier method will be used to estimate the median OS time and its 95% CI. |
| Secondary | Progression-free Survival | From the date of start of treatment to the date of event defined as the first documented progression or death due to any cause, assessed up to 60 months. | The Kaplan-Meier method will be used to estimate the median PFS time and its 95% CI. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Overall Response Rate | 24 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Overall Survival (OS) | From the date of start of treatment to date of death due to any cause, assessed up to 60 months | Months | MEDIAN | |
| SECONDARY | Progression-free Survival | From the date of start of treatment to the date of event defined as the first documented progression or death due to any cause, assessed up to 60 months. | Months | MEDIAN |
Source ClinicalTrials.gov
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Response Rate | Diffuse Large B-cell Lymphoma (DLBCL) | Complete Response | 1 | Participants | |
| Overall Response Rate | Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) | Complete Response | 1 | Participants | |
| Overall Response Rate | Diffuse Large B-cell Lymphoma (DLBCL) | Partial Response | 3 | Participants | |
| Overall Response Rate | Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) | Partial Response | 1 | Participants | |
| Overall Response Rate | Diffuse Large B-cell Lymphoma (DLBCL) | Stable disease | 5 | Participants | |
| Overall Response Rate | Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) | Stable disease | 3 | Participants | |
| Overall Response Rate | Diffuse Large B-cell Lymphoma (DLBCL) | Progressive disease | 34 | Participants | |
| Overall Response Rate | Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) | Progressive disease | 7 | Participants | |
| Overall Response Rate | Diffuse Large B-cell Lymphoma (DLBCL) | Not assessed | 4 | Participants | |
| Overall Response Rate | Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) | Not assessed | 1 | Participants |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Diffuse Large B-cell Lymphoma (DLBCL) | 47 | |
| Overall Study | STARTED | Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) | 13 | |
| Overall Study | COMPLETED | Diffuse Large B-cell Lymphoma (DLBCL) | 43 | |
| Overall Study | COMPLETED | Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) | 12 | |
| Overall Study | NOT COMPLETED | Diffuse Large B-cell Lymphoma (DLBCL) | 4 | |
| Overall Study | NOT COMPLETED | Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) | 1 |
Source ClinicalTrials.gov
Adverse events162
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Respiratory, thoracic and mediastinal disorder - Other | Respiratory, thoracic and mediastinal disorders | Diffuse Large B-cell Lymphoma (DLBCL) | 0 | 47 | |
| other | Respiratory, thoracic and mediastinal disorder - Other | Respiratory, thoracic and mediastinal disorders | Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) | 1 | 13 | |
| other | fatigue | General disorders | Diffuse Large B-cell Lymphoma (DLBCL) | 2 | 47 | |
| other | fatigue | General disorders | Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) | 2 | 13 | |
| other | hyponatremia | Metabolism and nutrition disorders | Diffuse Large B-cell Lymphoma (DLBCL) | 0 | 47 | |
| other | hyponatremia | Metabolism and nutrition disorders | Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) | 2 | 13 | |
| other | anemia | Blood and lymphatic system disorders | Diffuse Large B-cell Lymphoma (DLBCL) | 11 | 47 | |
| other | anemia | Blood and lymphatic system disorders | Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) | 1 | 13 | |
| other | apnea | Respiratory, thoracic and mediastinal disorders | Diffuse Large B-cell Lymphoma (DLBCL) | 0 | 47 | |
| other | apnea | Respiratory, thoracic and mediastinal disorders | Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) | 1 | 13 |
1 to 10 of 162Source ClinicalTrials.gov
See all 162 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Diffuse Large B-cell Lymphoma (DLBCL) | 31 | 47 |
| Total, all-cause mortality | Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) | 11 | 13 |
| Total, other adverse events | Diffuse Large B-cell Lymphoma (DLBCL) | 43 | 47 |
| Total, other adverse events | Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) | 12 | 13 |
| Total, serious adverse events | Diffuse Large B-cell Lymphoma (DLBCL) | 22 | 47 |
| Total, serious adverse events | Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) | 7 | 13 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 33942298 | DERIVED |
Source PubMed
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30CA036727 | Buffett Cancer Center Support Grant | SWEASY, JOANN B. | UNIVERSITY OF NEBRASKA MEDICAL CENTER | NATIONAL CANCER INSTITUTE | 1985 to 2025 |
Source NIH RePORTER
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Diffuse Large B-cell Lymphoma (DLBCL) vs Peripheral T-cell Non-Hodgkin Lymphoma (PTCL): deaths from any cause | Trial comparisons |
| Diffuse Large B-cell Lymphoma (DLBCL) vs Peripheral T-cell Non-Hodgkin Lymphoma (PTCL): serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01431209
GET https://conductscience.org/api/trials/v1/NCT01431209/events?page=2